Blog / Archives
Metrics of Pure Play Diagnostic Companies: Comparison to GenProbe
M&A Premium of Diagnostic Companies Bloomberg reported on April 29 that GenProbe (GPRO) was seeking a buyer. We reported earlier this month on the M&A trend in biotechnology, tools and...
Big Sell-Off in Oil, Gas and Other Commodities Spooks the Market
Relative Safety in Healthcare Stocks Today's sell-off in the energy complex with the back-drop of a U.S. slow growth scenario plus the Euro being vulnerable due to Greece and Ireland has spooked the...
Life Science Stocks Capture M&A Premium
Deals Are Bullish for the Market Yesterday's Alkermes (ALKS) deal with Elan (ELN) supports the major M&A trend in the life science market. Timing is everything in a hot market. The rationale for...
Life Science Stocks Are Deal Driven: Alkermes (ALKS) and Elan(ELN) Merge Technologies
Good Technology Fit Helped By Cheap Money and Tax Benefits M&A has been one of the main drivers of the biotech market and today we have more recombinant action as Alkermes (ALKS) of Boston is...
Upbeat Jobs Report Boosts Market But Rally Fading, Biotechs Are Strong
Biotechs Rally Unphased by Macro Concerns The market loved the jobs report after the nasty commodity meltdown yesterday but other news intervened and buyers left for the weekend. The Dow was up as...
Reporting from the Milken Conference: The Promise of Medical Science
An excellent perspective on the Medical Sciences in a panel by leading scientists was presented Monday at the Milken Institute Global Conference, "Shaping the Future" at the Beverly Hilton in Los...
Profit Taking Hits Biotechnology Stocks
Biotechnology Sector Steps Back after Meteoric Rise Since Early March With many life science indices reaching new highs both YTD and in some cases over 10 years traders decided it was time to put...
Health and Biotechnology: A Top Performing Sector YTD Up 13.2%
According to data compiled by the Wall Street Journal on Monday May 2 page R8, the Health and Biotechnology sectors led the market (excluding gold oriented funds) in 2011 up 13.2% YTD and 6.7% in...
Rayno Diagnostics and Tools Market Update: GenProbe (GPRO),Illumina (ILMN),Quidel (QDEL)
Earnings season has begun with good results. Keep in mind the following trends: technology convergence, molecular diagnostics and M&A. The backdrop for the tools market is proposed government...
Rayno Life Science Portfolio Dx and Tools: GenProbe (GPRO) Soars On “For Sale”
Earnings season for diagnostics and tools companies begins today with GenProbe (GPRO $79.39) after the market close. But the stock is up 13% today on a Bloomberg scoop that the Company has hired...